Shares of Arecor Therapeutics plc (LON:AREC – Get Free Report) were up 6.1% during trading on Thursday . The stock traded as high as GBX 70 and last traded at GBX 70. Approximately 12,959 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 23,612 shares. The stock had previously closed at GBX 66.
Arecor Therapeutics Stock Up 7.3%
The company has a market capitalization of £27.75 million, a PE ratio of 36.75 and a beta of -0.18. The firm’s 50-day simple moving average is GBX 63.09 and its 200 day simple moving average is GBX 66.60. The company has a debt-to-equity ratio of 1.52, a quick ratio of 6.24 and a current ratio of 4.35.
Arecor Therapeutics Company Profile
Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.
Read More
- Five stocks we like better than Arecor Therapeutics
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
- Amazon’s Zoox Push Tests Tesla’s Robotaxi Premium as Waymo Widens Its Lead
- MarketBeat Week in Review – 08/24 – 08/28
Receive News & Ratings for Arecor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arecor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
